Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to
Products are for professional/laboratory use only.
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US)
This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Products are for professional/laboratory use only.
For patients with advanced lung cancer, the expected median survival is approximately one year however treatment with targeted tyrosine kinase inhibitor (TKI) therapy can improve outcomes for patients who have certain molecular alterations that can be identified by molecular testing1.
Products are for professional/laboratory use only.
ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.
Products are for professional/laboratory use only.
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).